215600.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:30):

Stats
Dzisiejszy wolumen	521 393
Średni wolumen	1.08M
Kapitalizacja rynkowa	467.70B
EPS	KRW0 ( 2024-03-20 )
Następna data zysków	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW5.88 (0.13%)

Wolumen Korelacja

Długi: -0.17 (neutral)

Krótki: -0.62 (weak negative)

Signal:(56.326) Neutral

SillaJen, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SillaJen, Inc. Korelacja - Waluta/Towar

0.05
( neutral )

0.19
( neutral )

0.27
( neutral )

0.52
( weak )

0.24
( neutral )

-0.53
( weak negative )

SillaJen, Inc. Finanse

Annual	2023
Przychody:	KRW3.94B
Zysk brutto:	KRW-16.36B (-415.27 %)
EPS:	KRW-198.16

FY	2023
Przychody:	KRW3.94B
Zysk brutto:	KRW-16.36B (-415.27 %)
EPS:	KRW-198.16

FY	2022
Przychody:	KRW5.01B
Zysk brutto:	KRW-18.77B (-374.33 %)
EPS:	KRW-239.25

Financial Reports:

No articles found.

SillaJen, Inc.

SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.